Trials / Withdrawn
WithdrawnNCT06260267
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Microbiota suspension | Microbiota suspension |
| DRUG | Microbiota capsule | Microbiota capsule |
| DRUG | Placebo suspension | Placebo suspension |
| DRUG | Placebo capsule | Placebo capsule |
Timeline
- Start date
- 2024-03-12
- Primary completion
- 2026-01-15
- Completion
- 2026-01-15
- First posted
- 2024-02-15
- Last updated
- 2024-10-18
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06260267. Inclusion in this directory is not an endorsement.